Search research articles
Contact Us
Filters
Showing results (1-10 of 236) with videos related to
Page
of 24
Sort By:
Current Pharmaceutical Design
|
August 13, 2011
Tuberculosis; opportunities for treatment optimization
Jan-Willem C Alffenaar
The Journal of Infectious Diseases
|
March 31, 2012
Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs
Jan-Willem C Alffenaar
American Journal of Respiratory and Critical Care Medicine
|
October 24, 2025
Isoniazid for Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis; Does It Make Sense?
Jan-Willem C Alffenaar
The European Respiratory Journal
|
July 7, 2022
Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?
Alberto Matteelli, Jan-Willem C Alffenaar
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs
Tawanda Gumbo, Jan-Willem C Alffenaar
The European Respiratory Journal
|
August 31, 2023
Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development
Sophie L Stocker, Jan-Willem C Alffenaar
The Journal of Antimicrobial Chemotherapy
|
September 20, 2017
Treatment of Mycobacterium avium-intracellulare complex: a great leap forward
Jan-Willem C Alffenaar, Jakko van Ingen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 5, 2021
Investigator-Initiated Studies in Infectious Diseases-Considerations for Pharmacokinetic-Pharmacodynamic Optimization
Anne-Grete Märtson, Jan-Willem C Alffenaar
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2019
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs
Jan-Willem C Alffenaar, Vitali Sintchenko, Ben J Marais
Clinical Pharmacokinetics
|
April 4, 2024
Comment on "Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies" and "High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints"
Leping Kong, Jan-Willem C Alffenaar, Sophie L Stocker
Page
of 24
Search research articles
Search
Showing results (1-10 of 236) with videos related to
Sort By:
Page
of 24
Current Pharmaceutical Design
|
August 13, 2011
Tuberculosis; opportunities for treatment optimization
Jan-Willem C Alffenaar
The Journal of Infectious Diseases
|
March 31, 2012
Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs
Jan-Willem C Alffenaar
American Journal of Respiratory and Critical Care Medicine
|
October 24, 2025
Isoniazid for Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis; Does It Make Sense?
Jan-Willem C Alffenaar
The European Respiratory Journal
|
July 7, 2022
Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?
Alberto Matteelli, Jan-Willem C Alffenaar
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 30, 2018
Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs
Tawanda Gumbo, Jan-Willem C Alffenaar
The European Respiratory Journal
|
August 31, 2023
Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development
Sophie L Stocker, Jan-Willem C Alffenaar
The Journal of Antimicrobial Chemotherapy
|
September 20, 2017
Treatment of Mycobacterium avium-intracellulare complex: a great leap forward
Jan-Willem C Alffenaar, Jakko van Ingen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 5, 2021
Investigator-Initiated Studies in Infectious Diseases-Considerations for Pharmacokinetic-Pharmacodynamic Optimization
Anne-Grete Märtson, Jan-Willem C Alffenaar
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2019
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs
Jan-Willem C Alffenaar, Vitali Sintchenko, Ben J Marais
Clinical Pharmacokinetics
|
April 4, 2024
Comment on "Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies" and "High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints"
Leping Kong, Jan-Willem C Alffenaar, Sophie L Stocker
Page
of 24